Related Experiment Video
Updated: Mar 9, 2026
The Lambda Select cII Mutation Detection System
Published on: April 26, 2018
Development of an in vitro PIG-A gene mutation assay in human cells
Benjamin J Rees1, Matthew Tate2, Anthony M Lynch3
1Institute of Life Science, Swansea University Medical School, Singleton Park, Swansea SA2 8PP, UK.
Abstract:
Mutagens can be carcinogens, and traditionally, they have been identified in vitro using the Salmonella 'Ames' reverse mutation assay. However, prokaryotic DNA packaging, replication and repair systems are mechanistically very different to those in the humans we inevitably seek to protect. Therefore, for many years, mammalian cell line genotoxicity assays that can detect eukaryotic mutagens as well as clastogens and aneugens have been used. The apparent lack of specificity in these largely rodent systems, due partly to their mutant p53 status, has contributed to the use of animal studies to resolve data conflicts. Recently, silencing mutations at the PIG-A locus have been demonstrated to prevent glycophosphatidylinositol (GPI) anchor synthesis and consequentially result in loss of GPI-anchored proteins from the cell's extracellular surface. The successful exploitation of this mutant phenotype in animal studies has triggered interest in the development of an analogous in vitro PIG-A mutation screening assay. This article describes the development of a robust assay design using metabolically active human cells. The assay includes viability and cell membrane integrity assessment and conforms to the future ideas of the 21st-century toxicology testing.
Insights
This study introduces a new in vitro assay using human cells to screen for mutagens. This PIG-A mutation assay offers a more accurate alternative to traditional methods for predicting genotoxicity in humans.
Area of Science:
- Toxicology
- Genetics
- Cell Biology
Background:
- Traditional mutagenicity testing uses the Salmonella Ames assay, but prokaryotic systems differ significantly from human cells.
- Mammalian cell genotoxicity assays have been used, but rodent systems often lack specificity, necessitating animal studies.
- Recent advances identified PIG-A locus mutations affecting GPI-anchored proteins, prompting interest in a PIG-A mutation screening assay.
Purpose of the Study:
- To develop a robust in vitro PIG-A mutation screening assay using metabolically active human cells.
- To create a genotoxicity assay that is more relevant to human biology than traditional methods.
- To align with 21st-century toxicology testing principles.
Main Methods:
- Development of a PIG-A mutation assay utilizing metabolically active human cells.
- Incorporation of viability assessment to ensure cell health.
- Inclusion of cell membrane integrity assessment as a key metric.
Main Results:
- A robust assay design for PIG-A mutation screening in human cells was successfully developed.
- The assay incorporates essential viability and membrane integrity checks.
- The developed assay aligns with modern toxicology testing paradigms.
Conclusions:
- The PIG-A mutation assay provides a promising in vitro method for detecting eukaryotic mutagens.
- This human cell-based assay offers improved specificity and relevance compared to traditional methods.
- The assay represents a significant step towards 21st-century toxicology testing for genotoxicity.
